The latest financial reports from Taiwan’s biotechnology sector highlight S.C.P.C. as the top-earning pharmaceutical conglomerate for the past year. The group’s three major subsidiaries—S.C.P.C., Syn-Tech Chem & Pharm, and Syngen Biotech—achieved unprecedented revenue and profitability, securing their position as industry leaders. Notably, Syn-Tech reported an earnings per share (EPS) of NT$8.82, while S.C.P.C. itself posted a record-breaking EPS of NT$4.93, both accompanied by historically high dividend distributions. Analysts remain optimistic about the group's continued growth trajectory into 2025.
Specializing in active pharmaceutical ingredients (APIs), Syn-Tech saw its EPS soar to NT$8.82, propelled by favorable exchange rates and NT$75.2 million in insurance claims from a fire incident. The company reported a gross profit margin of 38.7%, marking an increase of nearly two percentage points year-over-year. The board has proposed a cash dividend of NT$5.3 per share.
Looking ahead, Syn-Tech is poised for further expansion, benefiting from increased production capacity following the resumption of full-scale operations. Additionally, its growing global market share in the central nervous system (CNS) drug segment and easing price competition from Chinese API manufacturers—due to ongoing U.S.-China trade tensions—are expected to drive near-double-digit revenue growth. Gross margins are projected to remain strong, with additional upside in operational profitability.
S.C.P.C., another key player in the group, achieved an EPS of NT$4.93 and plans to distribute a NT$2.8 per share dividend. The company is set to benefit from Taiwan’s recent National Health Insurance (NHI) policy revisions, which now grant the first two generic or biosimilar drugs approved for market entry the same pricing advantages as branded drugs. This regulatory shift has intensified competition among generic pharmaceutical companies, with S.C.P.C. strategically positioning itself to capitalize on these opportunities.
The company anticipates launching three to five new self-developed products this year. In the first half of 2024, two diabetes-related medications are expected to hit the market—one as Taiwan’s first generic equivalent and another as a Paragraph IV (P4) patent challenge product, granting it a one-year market exclusivity period. Additionally, a new antidiabetic and a psychiatric drug are slated for launch in the latter half of the year.
Beyond Taiwan, S.C.P.C. is actively expanding its international presence, with multiple drugs awaiting regulatory approval in the U.S., Japan, and China. The company is also exploring contract development and manufacturing organization (CDMO) services, which could further drive double-digit revenue growth this year.
Syngen Biotech, which shifted its business focus toward health supplements in 2017, has consistently delivered strong profitability. The company has maintained EPS above NT$10 for two consecutive years, and in 2023, it reported an EPS of NT$8.86—surpassing Syn-Tech to become the most profitable subsidiary in the group. The board has approved a cash dividend of NT$5 per share, the highest in the past three years.
One of Syngen Biotech’s most significant developments is its expansion into pharmaceutical-grade capsule production to address the global supply shortage. In May 2022, the company acquired Ding Yuan Biotech’s Douliu capsule manufacturing facility for NT$516 million. Following extensive upgrades, the facility is now in the final review stage with Taiwan’s Food and Drug Administration (TFDA) for PIC/S GMP certification, expected in Q1 2024. Once approved, the plant will contribute substantially to Syngen Biotech’s revenue.
Additionally, Syngen Biotech is actively seeking opportunities to expand its health supplement business into international markets. The company is exploring mergers, acquisitions, and strategic partnerships to accelerate global growth.
With record-breaking financial performances across all subsidiaries, S.C.P.C. is well-positioned for sustained profitability. Strategic product launches, international expansion, and regulatory advantages are expected to drive significant growth. Industry experts predict that 2025 will continue to be a prosperous year for the group, solidifying its leadership in Taiwan’s pharmaceutical and biotechnology sector.
Resource: 生達集團勇奪製藥獲利王 生達、生泰去年賺翻 締三高
